Does AXITINIB Cause Malignant neoplasm progression? 241 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 241 reports of Malignant neoplasm progression have been filed in association with AXITINIB (INLYTA). This represents 1.5% of all adverse event reports for AXITINIB.
241
Reports of Malignant neoplasm progression with AXITINIB
1.5%
of all AXITINIB reports
76
Deaths
58
Hospitalizations
How Dangerous Is Malignant neoplasm progression From AXITINIB?
Of the 241 reports, 76 (31.5%) resulted in death, 58 (24.1%) required hospitalization, and 9 (3.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for AXITINIB. However, 241 reports have been filed with the FAERS database.
What Other Side Effects Does AXITINIB Cause?
Death (2,222)
Diarrhoea (2,187)
Fatigue (1,816)
Neoplasm progression (1,315)
Hypertension (1,146)
Off label use (1,075)
Nausea (955)
Decreased appetite (920)
Dysphonia (871)
Disease progression (768)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which AXITINIB Alternatives Have Lower Malignant neoplasm progression Risk?
AXITINIB vs AZACITIDINE
AXITINIB vs AZATHIOPRINE
AXITINIB vs AZD-1222
AXITINIB vs AZELAIC ACID
AXITINIB vs AZELASTINE